Finding 1215556 (2025-001)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2025
Accepted
2026-05-26
Audit: 402221
Organization: Nexus Recovery Center Inc. (TX)

AI Summary

  • Core Issue: There is a significant deficiency in internal controls over compliance regarding allowable costs for Block Grants.
  • Impacted Requirements: The organization failed to document supervisor approvals for 2 out of 25 sampled transactions, violating federal regulations.
  • Recommended Follow-Up: Management should conduct training sessions for supervisors to emphasize the importance of documenting approvals before processing expenses.

Finding Text

Finding 2025‐001: Allowable Cost – Significant deficiency in internal controls over compliance. Block Grants for Prevention and Treatment of Substance Abuse ALN 93.959 Criteria: Section 200 of the Code of Federal Regulations requires recipients to implement robust internal controls to ensure compliance with cost principles for all transactions charged to the grant. The Organization’s control policies state that all Brex credit card charges are to be reviewed by the supervisor prior to being uploaded into the system. Condition: During allowable cost testing for federal grants, 2 out of the 25 sample items tested did not have documented approval from the supervisor. Cause: Due to oversight, a supervisor missed approving the charges. Effect: The Organization’s reporting of allowable costs is not fully documented in accordance with its internal control procedures over compliance. Questioned Cost: None Recommendation: Management should implement trainings with supervisors to reiterate the importance of the controls related to documentation of approval for all transactions prior to the expense being paid.

Corrective Action Plan

Finding 2025-001: Allowable Cost – Significant Deficiency in Internal Controls Over Compliance Program: Block Grants for Prevention and Treatment of Substance Abuse (ALN 93.959) Management Response: Management concurs with the finding. The exceptions identified resulted from a lapse in execution of established approval procedures, as 2 of the 25 sampled credit card transactions charged to the grant did not include documented supervisory approval prior to payment. However, compensating controls existed, including Finance Department review of all expenditures prior to payment of the Brex account and additional review of expenses charged to the grant during preparation of monthly grant invoices and reporting. No unallowable costs or, questioned costs, were identified. To remediate the finding, all supervisors have received additional training and reminders regarding requirements for timely review and approval of expenditures prior to payment processing. In addition, the accounting team has implemented procedures prohibiting payment processing until all required approvals have been completed and documented. Management believes these enhanced controls strengthen adherence to existing policies and reduce the likelihood of recurrence. Management notes that the supervisor associated with the exceptions is no longer employed by the Organization; however, corrective actions focus on strengthening processes and controls rather than reliance on personnel changes. Corrective Action Planned/Implemented: • Refresher training provided to supervisors regarding expenditure review and approval requirements. • Accounting procedures updated to prevent payment processing prior to completion and documentation of all required approvals. • Existing accounting department monitoring procedures will continue, including review of expenditures before payment and grant expenditure review during monthly reporting. Responsible Party: Controller / Accounting Department Implementation Date: Implemented as of April 2026

Categories

Allowable Costs / Cost Principles Internal Control / Segregation of Duties Reporting Significant Deficiency Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 1215548 2025-001
    Material Weakness Repeat
  • 1215549 2025-002
    Material Weakness Repeat
  • 1215550 2025-001
    Material Weakness Repeat
  • 1215551 2025-002
    Material Weakness Repeat
  • 1215552 2025-001
    Material Weakness Repeat
  • 1215553 2025-002
    Material Weakness Repeat
  • 1215554 2025-001
    Material Weakness Repeat
  • 1215555 2025-002
    Material Weakness Repeat
  • 1215557 2025-002
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $97,541